Developer docs
API playgroundTry for free, no card

Search company profiles

Hubble Therapeutics

Full company profile

uuid0002al9

Namestring
Hubble Therapeutics
Legal namestring
Hubble Therapeutics LLC
Websiteurl
hubbletx.com
Company typeenum
Private
Founded yearint
2000
Short descriptiontext

Hubble Therapeutics LLC is a private Hanover, NH-based biotechnology company developing HUB-101, an AAV-based gene therapy for rare inherited retinal diseases including Leber Congenital Amaurosis type 16 and Superficial Vascular Disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHanover, United States
HQ citystring
Hanover
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy, ophthalmology biotech, retinal diseases, AAV vectors, rare disease therapeutics
Industry4 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmology Gene Therapy
Social media profiles1 record
Revenue model1 record
1Gene Therapy Product (HUB-101)
TypeOne Time License
Description

Pre-revenue biotechnology company developing a novel gene therapy candidate (HUB-101) for LCA16 and SVD. Revenue will be generated upon successful FDA approval and commercialization of the therapy.

prnewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Hubble Therapeutics is a pre-clinical biotechnology company developing HUB-101, an AAV (adeno-associated virus) based gene therapy that delivers billions of healthy copies of the KCNJ13 gene to the Retinal Pigment Epithelium (RPE) layer to restore Kir7.1 ion channel function. The lead candidate targets Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two rare inherited pediatric blindness disorders caused by KCNJ13 gene mutations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase I/II clinical trials planned to begin in 2026
Product overview1 text field

Hubble Therapeutics is a patient-focused biotechnology company developing a single gene therapy product, HUB-101, for the treatment of Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). The company operates as a lean biotech with one lead candidate in the pipeline, having received FDA Rare Pediatric Disease Designation and Orphan Disease Designation for HUB-101, and has partnered with Andelyn Biosciences and Virscio for manufacturing and IND-enabling studies.

Product and service1 record
1HUB-101
CategoryGene Therapy / Biologic Drug Product
Description

HUB-101 is an AAV-based gene therapy candidate that delivers billions of healthy copies of the KCNJ13 gene directly to the Retinal Pigment Epithelium (RPE) layer to restore Kir7.1 ion channel function and treat Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). It is intended as a single one-time treatment addressing the genetic root cause of these rare inherited pediatric eye disorders.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-09
Description

Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), was selected to manufacture clinical grade AAV using its suspension AAV Curator Platform for the treatment of LCA16. Andelyn will optimize and scale-up the HUB-101 process, generate GMP-grade plasmids, and produce GMP vectors containing normal copies of the KCNJ13 gene for Phase 1/2 clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Virscio partnered with Hubble Therapeutics for manufacturing and IND-enabling studies supporting the HUB-101 gene therapy development program for LCA16.

Strategic tierCoreTypeTechnology or Integration
Description

The HUB-101 gene therapy technology was developed by Dr. Bikash Pattnaik at the University of Wisconsin-Madison and licensed from the Wisconsin Alumni Research Foundation. This licensing agreement provides Hubble Therapeutics rights to the proprietary gene therapy technology for KCNJ13 gene delivery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65 mutation/LCA2). Now part of Roche, Spark is the closest analog in ocular AAV gene therapy targeting Leber Congenital Amaurosis and sets the regulatory and commercial benchmark for Hubble's LCA16 program.

TypeDirect peer
Description

Clinical-stage gene editing company that has pursued LCA10 (a different LCA subtype) with EDIT-101, an AAV-delivered CRISPR therapy. Directly comparable in developing ocular gene therapy for inherited retinal dystrophies within the LCA family.

TypeDirect peer
Description

Clinical-stage gene therapy company with multiple AAV-based programs targeting inherited retinal diseases (e.g., X-linked retinitis pigmentosa, achromatopsia). Comparable in modality (AAV gene therapy), therapeutic area (inherited retinal disease), and stage (early clinical).

TypeDirect peer
Description

Clinical-stage AAV gene therapy company with ophthalmology programs (e.g., choroideremia, RPE65-related disease). Comparable in deploying next-generation AAV vectors for inherited retinal diseases.

TypeEmerging player
Description

Emerging ocular gene therapy company developing AAV-based treatments for X-linked retinitis pigmentosa and other inherited retinal diseases. Comparable focus area in inherited retinal dystrophies, though focused on different genetic targets.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for rare inherited retinal diseases (e.g., X-linked retinitis pigmentosa, achromatopsia). Highly comparable in modality, indication space, and stage of development.

TypeBroad incumbent
Description

Clinical-stage AAV gene therapy company with a broad pipeline including ocular programs (RGX-314 for wet AMD with AbbVie). Comparable in AAV platform technology and ophthalmology focus, though at later stage and broader scope.

TypeBroad incumbent
Description

Clinical-stage gene therapy company developing AAV-based treatments for ocular diseases (wet AMD, diabetic retinopathy). Comparable in AAV ocular delivery and rare ophthalmology positioning.

TypeEmerging player
Description

Clinical-stage gene therapy company developing optogenetic therapies for retinal degenerative diseases including retinitis pigmentosa. Comparable in targeting inherited retinal blindness with a one-time gene therapy approach, though using a different mechanism.

TypeEmerging player
Description

Clinical-stage RNA editing company developing therapies for inherited retinal diseases (e.g., Leber Congenital Amaurosis, Usher syndrome, retinitis pigmentosa). Comparable in targeting LCA and other inherited retinal diseases through genetic approaches, though using RNA rather than AAV gene replacement.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hubble Therapeutics

Ophthalmology Gene Therapyhubbletx.com

Hubble Therapeutics LLC is a private Hanover, NH-based biotechnology company developing HUB-101, an AAV-based gene therapy for rare inherited retinal diseases including Leber Congenital Amaurosis type 16 and Superficial Vascular Disease.

Hubble Therapeutics firmographics

Firmographics
Name
Hubble Therapeutics
Legal name
Hubble Therapeutics LLC
Website
https://hubbletx.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
1–10 employees
Short description
Hubble Therapeutics LLC is a private Hanover, NH-based biotechnology company developing HUB-101, an AAV-based gene therapy for rare inherited retinal diseases including Leber Congenital Amaurosis type 16 and Superficial Vascular Disease.
Ownership category
akta.pro rank

Hubble Therapeutics industry classification

Industry
Product category
Ophthalmology Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy
  • Ophthalmology biotech
  • Retinal diseases
  • AAV vectors
  • Rare disease therapeutics

Where Hubble Therapeutics is headquartered

Location

Headquarters

HQ city
Hanover
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Hubble Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Gene Therapy Product (HUB-101): Pre-revenue biotechnology company developing a novel gene therapy candidate (HUB-101) for LCA16 and SVD. Revenue will be generated upon successful FDA approval and commercialization of the therapy.

Distribution channels1 record

Marketing channels3 records

Hubble Therapeutics product offering

Product offering

Core offering

Hubble Therapeutics is a pre-clinical biotechnology company developing HUB-101, an AAV (adeno-associated virus) based gene therapy that delivers billions of healthy copies of the KCNJ13 gene to the Retinal Pigment Epithelium (RPE) layer to restore Kir7.1 ion channel function. The lead candidate targets Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two rare inherited pediatric blindness disorders caused by KCNJ13 gene mutations.

Product overview

Hubble Therapeutics is a patient-focused biotechnology company developing a single gene therapy product, HUB-101, for the treatment of Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). The company operates as a lean biotech with one lead candidate in the pipeline, having received FDA Rare Pediatric Disease Designation and Orphan Disease Designation for HUB-101, and has partnered with Andelyn Biosciences and Virscio for manufacturing and IND-enabling studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • HUB-101 HUB-101 is an AAV-based gene therapy candidate that delivers billions of healthy copies of the KCNJ13 gene directly to the Retinal Pigment Epithelium (RPE) layer to restore Kir7.1 ion channel function and treat Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). It is intended as a single one-time treatment addressing the genetic root cause of these rare inherited pediatric eye disorders.

Quantifiable outcome

  • Phase I/II clinical trials planned to begin in 2026

Companies that use Hubble Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Hubble Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Hubble Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Andelyn BiosciencescoreTechnology or Integration · 9 October 2024Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), was selected to manufacture clinical grade AAV using its suspension AAV Curator Platform for the treatment of LCA16. Andelyn will optimize and scale-up the HUB-101 process, generate GMP-grade plasmids, and produce GMP vectors containing normal copies of the KCNJ13 gene for Phase 1/2 clinical trials.
  • VirsciocoreStrategic or Co-development PartnerVirscio partnered with Hubble Therapeutics for manufacturing and IND-enabling studies supporting the HUB-101 gene therapy development program for LCA16.
  • Wisconsin Alumni Research Foundation (WARF)coreTechnology or IntegrationThe HUB-101 gene therapy technology was developed by Dr. Bikash Pattnaik at the University of Wisconsin-Madison and licensed from the Wisconsin Alumni Research Foundation. This licensing agreement provides Hubble Therapeutics rights to the proprietary gene therapy technology for KCNJ13 gene delivery.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Hubble Therapeutics competitors and assessment

Company assessment

Direct peers

  • Spark Therapeutics: Developer of Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65 mutation/LCA2). Now part of Roche, Spark is the closest analog in ocular AAV gene therapy targeting Leber Congenital Amaurosis and sets the regulatory and commercial benchmark for Hubble's LCA16 program.
  • Editas Medicine: Clinical-stage gene editing company that has pursued LCA10 (a different LCA subtype) with EDIT-101, an AAV-delivered CRISPR therapy. Directly comparable in developing ocular gene therapy for inherited retinal dystrophies within the LCA family.
  • MeiraGTx Holdings: Clinical-stage gene therapy company with multiple AAV-based programs targeting inherited retinal diseases (e.g., X-linked retinitis pigmentosa, achromatopsia). Comparable in modality (AAV gene therapy), therapeutic area (inherited retinal disease), and stage (early clinical).
  • 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company with ophthalmology programs (e.g., choroideremia, RPE65-related disease). Comparable in deploying next-generation AAV vectors for inherited retinal diseases.
  • Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy company developing AAV-based treatments for rare inherited retinal diseases (e.g., X-linked retinitis pigmentosa, achromatopsia). Highly comparable in modality, indication space, and stage of development.

Emerging players

  • Beacon Therapeutics: Emerging ocular gene therapy company developing AAV-based treatments for X-linked retinitis pigmentosa and other inherited retinal diseases. Comparable focus area in inherited retinal dystrophies, though focused on different genetic targets.
  • Nanoscope Therapeutics: Clinical-stage gene therapy company developing optogenetic therapies for retinal degenerative diseases including retinitis pigmentosa. Comparable in targeting inherited retinal blindness with a one-time gene therapy approach, though using a different mechanism.
  • ProQR Therapeutics: Clinical-stage RNA editing company developing therapies for inherited retinal diseases (e.g., Leber Congenital Amaurosis, Usher syndrome, retinitis pigmentosa). Comparable in targeting LCA and other inherited retinal diseases through genetic approaches, though using RNA rather than AAV gene replacement.

Broad incumbents

  • REGENXBIO: Clinical-stage AAV gene therapy company with a broad pipeline including ocular programs (RGX-314 for wet AMD with AbbVie). Comparable in AAV platform technology and ophthalmology focus, though at later stage and broader scope.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based treatments for ocular diseases (wet AMD, diabetic retinopathy). Comparable in AAV ocular delivery and rare ophthalmology positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Hubble Therapeutics social profiles

Digital presence

Hubble Therapeutics compliance and trust

Trust signal

Compliance2 records

Hubble Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hubble Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Hubble Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hubble Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hubble Therapeutics

What does Hubble Therapeutics do?

Hubble Therapeutics is a pre-clinical biotechnology company developing HUB-101, an AAV (adeno-associated virus) based gene therapy that delivers billions of healthy copies of the KCNJ13 gene to the Retinal Pigment Epithelium (RPE) layer to restore Kir7.1 ion channel function. The lead candidate targets Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two rare inherited pediatric blindness disorders caused by KCNJ13 gene mutations.

Is Hubble Therapeutics a public or private company?

Hubble Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hubble Therapeutics founded?

Hubble Therapeutics was founded in 2000. It employs 1 to 10 people.

Where is Hubble Therapeutics based?

Hubble Therapeutics is headquartered in Hanover, United States, in the North America region.

How does Hubble Therapeutics make money?

One revenue line is on record: gene Therapy Product (HUB-101).

Who are Hubble Therapeutics's main competitors?

Direct peers on record are Spark Therapeutics, Editas Medicine, MeiraGTx Holdings, 4D Molecular Therapeutics and Applied Genetic Technologies Corp (AGTC). Emerging players are Beacon Therapeutics, Nanoscope Therapeutics and ProQR Therapeutics. Broad incumbents are REGENXBIO and Adverum Biotechnologies.

Does Hubble Therapeutics have an API?

No public API is recorded for Hubble Therapeutics.

What industry is Hubble Therapeutics in?

Hubble Therapeutics's product category is Ophthalmology Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 541714 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Hubble Therapeutics: $7.3 Million (Series A) Raised For Developing Gene Therapy Cure For LCA16Hubble Therapeutics closed a $7.3 million Series A round to advance its gene therapy HUB-101 for LCA16 and SVD into human clinical trials. The therapy targets KCNJ13 mutations causing early-onset retinal degeneration. The company expects to enter Phase I/II trials in 2026.FinSMEsHubble Therapeutics Closes $7.3M Series A FinancingHubble Therapeutics raised $7.3M in Series A funding to advance its gene therapy HUB-101 for pediatric blindness. The company expects to enter Phase I/II clinical trials in 2026. Backers were not disclosed.PR NewswireHubble Therapeutics conclut un financement de série A pour développer une thérapie génique contre l'ACL16Hubble Therapeutics LLC, a patient-focused biotechnology company based in Hanover, New Hampshire, announced the successful completion of a $7.3 million Series A financing round to advance its gene therapy candidate HUB-101 into human clinical trials. The therapy targets Leber congenital amaurosis type 16 (LCA16) and snowflake vitreoretinal degeneration (SVD), two rare pediatric eye diseases caused by KCNJ13 gene mutations that lead to progressive retinal degeneration and eventual blindness. The company has received rare pediatric disease and orphan disease designations from the FDA and plans to enter Phase I/II clinical trials in 2026, having partnered with Andelyn Biosciences and Virscio for development, manufacturing, and regulatory submission studies.PR NewswireHubble Therapeutics schließt Serie A-Finanzierung zur Entwicklung einer Gentherapie zur Behandlung von LCA16 abHubble Therapeutics LLC announced the successful completion of a $7.3 million Series A financing round to advance its gene therapy candidate HUB-101 into human clinical trials. The therapy targets LCA16 and SVD, two rare inherited eye diseases caused by KCNJ13 gene mutations that lead to progressive retinal degeneration and blindness in children. The company has received FDA Rare Pediatric Disease Designation and Orphan Disease Designation, with plans to enter clinical phase in 2026.PR NewswireHubble Therapeutics desarrollará una cura de terapia génica para LCA16Hubble Therapeutics LLC announced the successful closing of a $7.3 million Series A funding round to advance its lead gene therapy candidate, HUB-101, into human clinical trials. The therapy targets LCA16 (Leber Congenital Amaurosis type 16) and SVD (Snowflake Vitreoretinal Degeneration), two rare pediatric ocular disorders caused by mutations in the KCNJ13 gene that lead to progressive retinal degeneration and eventual blindness. The company has partnered with Andelyn Biosciences and Virscio for manufacturing and IND-enabling studies, and plans to initiate Phase I/II clinical trials in 2026, with the therapy already having received Rare Pediatric Disease and Orphan Drug designations from the FDA.PR NewswireHubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16Hubble Therapeutics LLC announced the successful closing of a $7.3 million Series A funding round to advance its gene therapy candidate HUB-101 into human clinical trials for the treatment of Leber Congenital Amaurosis (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two rare pediatric eye disorders that cause progressive vision loss and blindness. The therapy, developed by Dr. Bikash Pattnaik at the University of Wisconsin-Madison and licensed from the Wisconsin Alumni Research Foundation, has received both Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA. The company has partnered with Andelyn Biosciences and Virscio for manufacturing and IND-enabling studies, with Phase I/II trials expected to begin in 2026.PR NewswireHubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16Hubble Therapeutics LLC announced the successful closing of a $7.3 million Series A funding round to advance its lead gene therapy candidate HUB-101 into human clinical trials for the treatment of Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). The therapy targets rare pediatric blindness disorders caused by KCNJ13 gene mutations and has received Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA. The company has partnered with Andelyn Biosciences and Virscio for manufacturing and IND-enabling studies, with Phase I/II trials expected to begin in 2026.YahooHubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16Hubble Therapeutics closed a $7.3 million Series A funding round to advance its gene therapy HUB-101 for LCA16 and SVD into human clinical trials. The therapy, developed by Dr. Bikash Pattnaik and licensed from WARF, has received FDA Rare Pediatric and Orphan Disease Designations. The company expects to enter Phase I/II trials in 2026.VC News DailyHubble Therapeutics Announces $7.3M Series AHubble Therapeutics LLC announced the successful closing of a $7.3 million Series A funding round to advance its lead candidate HUB-101 into human clinical trials. The biotechnology company is developing a gene therapy from Professor Bikash Pattnaik's lab at the University of Wisconsin-Madison to treat Leber Congenital Amaurosis Type 16 and Snowflake Vitreoretinal Degeneration, two debilitating retinal diseases causing severe vision loss in pediatric and adult patients.YahooHubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16Hubble Therapeutics LLC announced the successful closing of a $7.3 million Series A funding round to advance its lead gene therapy candidate HUB-101 into human clinical trials. The therapy targets Leber Congenital Amaurosis (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two rare pediatric blindness disorders caused by KCNJ13 gene mutations, and has received Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA. The company expects to enter Phase I/II clinical trials in 2026 and has partnered with Andelyn Biosciences and Virscio for development and manufacturing.